NCT05071209 2026-01-23Elimusertib for the Treatment of Relapsed or Refractory Solid TumorsNational Cancer Institute (NCI)Phase 1/2 Active not recruiting31 enrolled 14 charts
NCT03188965 2023-10-11First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and LymphomasBayerPhase 1 Completed229 enrolled